Pharmacodynamic modeling of the effects of lanreotide autogel on growth hormone and insulin-like growth factor 1

Journal of Clinical Pharmacology

Volumn 52, Issue 4, 2012, Pages 487-498

  Garrido, María J ^a   Cendrós, Josep María ^b   Ramis, Joaquim ^b   Peraire, Concepción ^b   Obach, Rosendo ^b   Trocóniz, Iñaki F ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b IPSEN   (France)

Author keywords

acromegaly; hormone effects; lanreotide; NONMEM; population modeling

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; SOMATOMEDIN C;

ACROMEGALY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; HORMONAL REGULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; POPULATION MODEL; RANDOMIZED CONTROLLED TRIAL;

ACROMEGALY; ADULT; AGED; AGED, 80 AND OVER; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GELS; GROWTH HORMONE; HUMANS; INJECTIONS, SUBCUTANEOUS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; PEPTIDES, CYCLIC; SINGLE-BLIND METHOD; SOMATOSTATIN; YOUNG ADULT;

EID: 84858041338     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011399761     Document Type: Article

References (29)

1. Clemmons DR. Role of insulin-like growth factor-I in diagnosis and management of acromegaly. Endocr Pract. 2004;10(4):362-371.
2. Melmed S. Acromegaly. N Engl J Med. 2006;355(24):2558-2573.
3. Trocóniz IF, Cendrós JM, Peraire C, et al. Population pharmacokinetic analysis of lanreotide Autogel in healthy subjects: evidence for injection interval of up to 2 months. Clin Pharmacokinet. 2009;48(1):51-62.
4. Lucas T, Astorga R; Spanish-Portuguese Multicentre Autogel Study Group on Acromegaly. Efficacy of lanreotide Autogel® administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial. Clin Endocrinol. 2006;65(3):320-326.
5. Ronchi CL, Boschetti M, Degli Uberti EC, et al. Efficacy of aslow-release formulation of lanreotide (Autogel 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clin Endocrinol. 2007;67(4):512-519. (Pubitemid 47416307)
6. Bevan JS, Newell-Price J, Wass JA, et al. Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective. Clin Endocrinol. 2008;68(3):343-349. (Pubitemid 351257850)
7. Chanson P, Borson-Chazot F, Kuhn JM, et al. Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. Clin Endocrinol. 2008;69(2):299-305. (Pubitemid 352009031)
8. Cendros JM, Peraire C, Trocóniz IF, et al. Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel. Metabolism. 2005;54(10):1276-1281. (Pubitemid 41262582)
9. Comets E, Mentré F, Grass P, et al. Population pharmacodynamic analysis ofoctreotide in acromegalic patients. Clin Pharmacol Ther. 2003;73(1):95-106. (Pubitemid 36158491)
10. Zhou H, Chen TL, Marino M, et al. Population PKand PK/PD modeling of microencapsulated octreotide acetate in healthy subjects. Br J Clin Pharmacol. 2000;50(6):543-552. (Pubitemid 32010015)
11. Melmed S, Cook D, Schopohl J, Goth MI, Lam KS, Marek J. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel® therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary. 2010;13(1):18-28.
12. Barbanoj M, Antonijoan R, Morte A, et al. Pharmacokinetics of the somatostatin analog lanreotide in patients with severe chronic renal insufficiency. Clin Pharmacol Ther. 1999;66(5):485-491.
13. Beal SL, Sheiner LS, eds. Users Guides, NONMEM. Elliot City, MD: Icon Development Solutions.
14. Petersson KJ, Hanze E, Savic RM, Karlsson MO. Semiparametric distributions with estimated shape parameters. Pharm Res. 2009;26(9):2174-2185.
15. Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN): aPerl module for NONMEM related programming. Comput Methods Programs Biomed. 2004;75(2):85-94. (Pubitemid 38798039)
16. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther. 1979;25(3):358-371. (Pubitemid 9164953)
17. Dayneka NL, Garg V, Jusko WJ. Comparison off our basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm. 1993;21(4):457-478. (Pubitemid 24025269)
18. Chan PL, Holford NH. Drug treatment effects ondisease progression. Annu Rev Pharmacol Toxicol. 2001;41:625-659. (Pubitemid 32385901)
19. Karlsson MO, Holford NH. A tutorial on visual predictive checks. PAGE. 2008;17:abstract 1434. www.page-meeting.org/?abstract=1434
20. Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009;94(5):1509-1517.
21. Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther. 2007;82(1):17-20. (Pubitemid 46944205)
22. Hooker AC, Staatz CE, Karlsson MO. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res. 2007;24(12):2187- 2197. (Pubitemid 350060706)
23. Jonsson EN, Karlsson MO. Xpose: anS-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58(1):51-64. (Pubitemid 29049052)
24. Steffin B, Gutt B, Bidlingmaier M. Effects of the long-acting somatostatin analogue lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly. Eur J Endocrinol. 2006;155(1):73-78. (Pubitemid 44103377)
25. Higham CE, Jostel A, Trainer PJ. IGF-I measurements inthe monitoring of GH therapy. Pituitary. 2007;10(2):159-163. (Pubitemid 46863730)
26. Frystyk J, Freda P, Clemmons DR. The current status of IGF-I assays: a 2009 update. Growth Horm IGF Res. 2010;20(1):8-18.
27. Colao A, Auriemma RS, Rebora A. Significant tumour shrinkage alter 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly. Clin Endocrinol. 2009;71(2):237-245.
28. Lucas T, Astorga R. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial. Clin Endocrinol. 2006;65(3):320-326.
29. Lombardi G, Minuto F, Tamburrano G. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naïve patients with acromegaly. J Endocrinol Invest. 2009;32(3):202-209.